Combination Treatment Strategies to Overcome PARP Inhibitor Resistance

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2023 Oct 28

PMID 37892162

Authors

Young-Hwa Soung

Jun Chung

Affiliations

Soon will be listed here.

Abstract

Poly(ADP-ribose) polymerase (PARP) enzymes have been shown to be essential for DNA repair pathways, including homologous recombination repair (HRR). Cancers with HRR defects (e.g., BRCA1 and BRCA2 mutations) are targets for PARP inhibitors (PARPis) based on the exploitation of "synthetic lethality". As a result, PARPis offer a promising treatment option for advanced ovarian and breast cancers with deficiencies in HRR. However, acquired resistance to PARPis has been reported for most tumors, and not all patients with BRCA1/2 mutations respond to PARPis. Therefore, the formulation of effective treatment strategies to overcome resistance to PARPis is urgently necessary. This review summarizes the molecular mechanism of therapeutic action and resistance to PARPis, in addition to emerging combination treatment options involving PARPis.

Citing Articles

SPHK1 enhances olaparib resistance in ovarian cancer through the NFκB/NRF2/ferroptosis pathway.

Teng K, Ma H, Gai P, Zhao X, Qi G Cell Death Discov. 2025; 11(1):29.

PMID: 39875359 PMC: 11775125. DOI: 10.1038/s41420-025-02309-y.

PARP inhibitors in prostate cancer: clinical applications.

Saeidi H, Sarafbidabad M Mol Biol Rep. 2024; 51(1):1103.

PMID: 39476131 DOI: 10.1007/s11033-024-10034-5.

Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in the Treatment of Advanced Ovarian Cancer: A Narrative Review.

Dewani D, Jaiswal A, Karwade P Cureus. 2024; 16(9):e68463.

PMID: 39360040 PMC: 11446491. DOI: 10.7759/cureus.68463.

Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options.

Nunes M, Bartosch C, Abreu M, Richardson A, Almeida R, Ricardo S Cells. 2024; 13(9.

PMID: 38727322 PMC: 11083313. DOI: 10.3390/cells13090786.

Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer.

Fountzilas E, Papadopoulou K, Chatzikonstantinou T, Karakatsoulis G, Constantoulakis P, Tsantikidi A Cancers (Basel). 2023; 15(23).

PMID: 38067228 PMC: 10705222. DOI: 10.3390/cancers15235525.

References

Frampton G, Fichtenholtz A, Otto G, Wang K, Downing S, He J . Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31(11):1023-31. PMC: 5710001. DOI: 10.1038/nbt.2696. View

Coleman R, Fleming G, Brady M, Swisher E, Steffensen K, Friedlander M . Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019; 381(25):2403-2415. PMC: 6941439. DOI: 10.1056/NEJMoa1909707. View

Lee Y, Lim M, Kim B, Ngoi N, Choi C, Park S . A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). J Gynecol Oncol. 2021; 32(2):e31. PMC: 7930449. DOI: 10.3802/jgo.2021.32.e31. View

Rondinelli B, Gogola E, Yucel H, Duarte A, van de Ven M, van der Sluijs R . EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol. 2017; 19(11):1371-1378. DOI: 10.1038/ncb3626. View

Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonzalez-Martin A, Marth C . Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2023; 34(8):681-692. DOI: 10.1016/j.annonc.2023.05.005. View

Sieber O, Heinimann K, Tomlinson I . Genomic instability--the engine of tumorigenesis?. Nat Rev Cancer. 2003; 3(9):701-8. DOI: 10.1038/nrc1170. View

Strickland K, Howitt B, Shukla S, Rodig S, Ritterhouse L, Liu J . Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016; 7(12):13587-98. PMC: 4924663. DOI: 10.18632/oncotarget.7277. View

Lallo A, Frese K, Morrow C, Sloane R, Gulati S, Schenk M . The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. Clin Cancer Res. 2018; 24(20):5153-5164. DOI: 10.1158/1078-0432.CCR-17-2805. View

Brandsma I, Fleuren E, Williamson C, Lord C . Directing the use of DDR kinase inhibitors in cancer treatment. Expert Opin Investig Drugs. 2017; 26(12):1341-1355. PMC: 6157710. DOI: 10.1080/13543784.2017.1389895. View

10.

Helleday T . Pathways for mitotic homologous recombination in mammalian cells. Mutat Res. 2003; 532(1-2):103-15. DOI: 10.1016/j.mrfmmm.2003.08.013. View

11.

Godin S, Sullivan M, Bernstein K . Novel insights into RAD51 activity and regulation during homologous recombination and DNA replication. Biochem Cell Biol. 2016; 94(5):407-418. PMC: 5045787. DOI: 10.1139/bcb-2016-0012. View

12.

Vaidyanathan A, Sawers L, Gannon A, Chakravarty P, Scott A, Bray S . ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 2016; 115(4):431-41. PMC: 4985349. DOI: 10.1038/bjc.2016.203. View

13.

Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte A, Lee J . Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016; 535(7612):382-7. PMC: 4959813. DOI: 10.1038/nature18325. View

14.

Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M, Hsu J . PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017; 23(14):3711-3720. PMC: 5511572. DOI: 10.1158/1078-0432.CCR-16-3215. View

15.

Gudmundsdottir K, Ashworth A . The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006; 25(43):5864-74. DOI: 10.1038/sj.onc.1209874. View

16.

Cejka P . DNA End Resection: Nucleases Team Up with the Right Partners to Initiate Homologous Recombination. J Biol Chem. 2015; 290(38):22931-8. PMC: 4645618. DOI: 10.1074/jbc.R115.675942. View

17.

Norquist B, Wurz K, Pennil C, Garcia R, Gross J, Sakai W . Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011; 29(22):3008-15. PMC: 3157963. DOI: 10.1200/JCO.2010.34.2980. View

18.

Sun Y, Jiang X, Chen S, Fernandes N, Price B . A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc Natl Acad Sci U S A. 2005; 102(37):13182-7. PMC: 1197271. DOI: 10.1073/pnas.0504211102. View

19.

Murai J, Huang S, Renaud A, Zhang Y, Ji J, Takeda S . Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2013; 13(2):433-43. PMC: 3946062. DOI: 10.1158/1535-7163.MCT-13-0803. View

20.

Helleday T . The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011; 5(4):387-93. PMC: 5528309. DOI: 10.1016/j.molonc.2011.07.001. View